Psoriasis

Psoriasis (PsO)

One of the most common skin diseases, affecting 3 million people in the U.S. alone, psoriasis is the result of an overactive immune system, causing skin cells to multiply too quickly forming scaly patches on the skin.

Mild psoriasis can treated with creams or ointments, while moderate but severe psoriasis may require pills or injections.¹

https://www.niams.nih.gov/health-topics/psoriasis

PremiOM PsO Dataset Overview

| Use Case

Treatment effectiveness by patient subtype in psoriasis patients

Challenge

Understanding treatment choice in the real world across specific PsO subtypes such as scalp and nail psoriasis
Measuring the effectiveness of individual treatments in minimizing the disease impact in specific subtypes.

Solution

Leverage linked OM1 clinical and claims data to see presence of PsO subtype as well as other key outcomes including %BSA to better understand how patients on specific treatments respond differently.

| Use Case

Assess the potential positive cardiometabolic effects of specific psoriasis drug treatments in patients

Challenge

Understanding if specific treatments that demonstrated beneficial effects on cardiometabolic markers during randomized clinical trials can be shown using real world data, while controlling for confounders.

Solution

Leverage OM1 linked clinical EMR and claims data to better understand the role of specific Psoriasis treatments on longer-term cardiovascular comorbidities.

| Use Case

Understand the clinical journey for patients with Psoriasis

Challenge

As objective disease severity scales (BSA, IGA) are not often collected in real-world clinical practice, longitudinal therapeutic escalation can serve as a good surrogate for disease severity.

Solution

Leverage OM1 linked, deep clinical and claims data to illustrate the longitudinal clinical treatment progression and associated outcomes.